panitumumab
information and resources from the National Cancer Institute
panitumumab
A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Monoclonal antibody ABX-EGF may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation. panitumumab
A human monoclonal antibody produced in transgenic mice that attaches to the transmembrane epidermal growth factor (EGF) receptor. Monoclonal antibody ABX-EGF may inhibit autocrine EGF stimulation of tumor cells that express the EGF receptor, thereby inhibiting tumor cell proliferation.
|
|
|
|
news articles
Scientists, Physicians Assemble at Annual Meeting to Discuss ... 01 Apr 2006
Newswise (press release) Press briefings: COX-2 inhibitors for cancer prevention; panitumumab for treatment of colorectal cancer; health disparities in cancer care and etiology; early ...
Demand to expand Mar 28, 2006
TMCnet One potential candidate, panitumumab, has exceeded expectations in clinical trials. ... The two companies have been developing panitumumab together. ...
Amgen (AMGN) and Abgenix (ABGX) Complete Biologic License ... Mar 30, 2006
StreetInsider.com (subscription), ABGX) announced that Amgen has completed the Biologic License Application (BLA) submission with the US Food and Drug Administration (FDA) for panitumumab. ...
UPDATE 1-Abgenix says shareholders approve Amgen deal Mar 29, 2006
Reuters Thousand Oaks, California-based Amgen and Abgenix have been developing an antibody-based cancer drug, called panitumumab, that is designed to work by blocking ...
Trader Joe's to open new site in Walnut Creek Mar 29, 2006
San Jose Mercury News, Amgen, based in Thousand Oaks, is acquiring Abgenix to gain full rights to the panitumumab colon-cancer drug that the companies developed together. ...
ImClone’s Erbitux Receives FDA Label In Head And Neck Cancer Mar 2, 2006
BioWorld Online (subscription), ...to acquire Abgenix Inc., of Fremont, Calif., for $22.50 a share, or about $2.2 billion in cash, which is how Amgen got the colorectal cancer drug panitumumab. ...
Amgen "buy" Mar 20, 2006
newratings.com ...note published this morning, the analyst mentions that the company is scheduled to announce the pivotal Phase III study results of panitumumab as monotherapy ...
Amgen Eyes Wider Market Reach With Osteoporosis Drug Mar 10, 2006
Investor's Business Daily (subscription) Amgen's drugs dubbed AMG 706 and Panitumumab are being studied against certain cancers, while AMG 531 is being tested against an autoimmune bleeding disorder. ...
Biotechs may be a good bet for 2006 21 Dec 2005
CNN Amgen (up $0.85 to $78.48, Research), the world's largest biotech, is collaborating with Abgenix on a colon cancer drug called panitumumab that showed positive ...
Zacks.com announces that Nadine Wong highlights: Abgenix and Amgen 21 Dec 2005
Business Wire (press release), ...gave a thumb ups on Abgenix (NASDAQ:ABGX) giving it a target price of $17 based on the announcement of a positive Phase III study of panitumumab in patients ...
Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With ... Dec 14, 2005
PharmaLive.com (press release), The acquisition of Abgenix provides Amgen with full ownership of one of its most important advanced pipeline products, panitumumab. ...
Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With ... Dec 15, 2005
boerse.de (Pressemitteilung), The acquisition of Abgenix provides Amgen with full ownership of one of its most important advanced pipeline products, panitumumab. ...
Amgen to acquire Abgenix for about $2.2 billion Dec 14, 2005
Reuters ...hours trading. If approved by regulators, the drug, called panitumumab, would be the first cancer treatment from Amgen. The company ...
Amgen Buys a Potential Blockbuster Dec 15, 2005
BusinessWeek ...largest biotech. Amgen and Abgenix have been working together to develop a drug called Panitumumab, a treatment for colon cancer. The ...
Amgen Buys Abgenix for $2.2B Dec 15, 2005
Red Herring, The two companies have been partnering on developing a cancer treatment known as panitumumab since 2002, when Amgen acquired Immunex. ...
Amgen to Buy Drug Firm Dec 15, 2005
Los Angeles Times, The deal to buy Abgenix Inc. would give Amgen full ownership of Panitumumab, a cancer drug the two companies had been developing for colon cancer. ...
Amgen to acquire Abgenix for about $2.2 billion Dec 14, 2005
Reuters ...per share in 2006 and 2007 by 5 cents to 10 cents, and to add to earnings thereafter, assuming commercial success of experimental cancer drug panitumumab. ...
Amgen to Buy Abgenix, Getting Complete Control of New Colon Cancer ... Dec 14, 2005
New York Times, The main prize for Amgen is full ownership of panitumumab, which slowed the progression of advanced colorectal cancer in a late-stage clinical trial. ...
Giant Amgen snaps up Abgenix Dec 14, 2005
San Francisco Business Times, The deal gives Amgen full ownership of panitumumab, which the companies have co-developed. Panitumumab is a new class of drugs that ...
Amgen to Acquire Abgenix for $2.2 Billion in Cash (Update3) Dec 14, 2005
Bloomberg ...``This investment reflects Amgen's commitment to our pipeline and our growing confidence in the future success of both panitumumab and denosumab.''. ...
Amgen to Acquire Abgenix for $2.2 Billion in Cash (Update4) Dec 14, 2005
Bloomberg The companies have been partners in developing panitumumab, the colon-cancer treatment. ... Panitumumab could take market share from ImClone Systems Inc. ...
Amgen to acquire Abgenix for $2.2 billion Dec 15, 2005
San Jose Mercury News, But company officials said the Abgenix acquisition was largely driven by the development of panitumumab, which has shown evidence it could substantially reduce ...
Amgen to buy Abgenix Dec 14, 2005
Providence Journal (subscription), The two companies have been partners in developing panitumumab, a colon-cancer treatment, of which Amgen will acquire full ownership. ...
Amgen to Acquire Abgenix for $22.50 Per Share Dec 14, 2005
PR Newswire (press release), Provides Amgen With Full Ownership of Panitumumab and Eliminates a Denosumab Royalty $0.05 to $0.10 Dilution of Adjusted Earnings Per Share in 2006 and 2007 ...
Amgen to Acquire Abgenix for $2.2 Billion in Cash (Update2) Dec 14, 2005
Bloomberg The two companies have been partners in the developing panitumumab, the colon-cancer treatment. ... Panitumumab would compete with ImClone Systems Inc. ...
Amgen to acquire Abgenix Dec 14, 2005
ABC News ...are developing. If approved by regulators, the drug, called panitumumab, would be the first cancer treatment from Amgen. The company ...
Amgen agrees to spend $2.2bn cash for Abgenix Dec 14, 2005
MSN Money The companies already had close ties because of a co-development agreement for the key product, panitumumab, which recently completed final phase III trials ...
Amgen pursues partner Dec 15, 2005
San Francisco Chronicle, Amgen executives said the decisive factor behind the purchase offer was the potential for the cancer drug candidate panitumumab, which delayed the advance of ...
Amgen Keeps the Profit Dec 16, 2005
Motley Fool The two companies had been collaborating on two cancer therapies, the colorectal cancer drug panitumumab, and the bone cancer and osteoporosis drug denosumab. ...
2ND UPDATE: Amgen To Buy Abgenix For $2.2 Bln Dec 14, 2005
Business Online, BOSTON (Dow Jones) -- In a move to gain complete control over their jointly-developed new cancer treatment panitumumab, Amgen announced Wednesday that it will ...
Amgen to Acquire Abgenix for $22.50 Per Share; Provides Amgen With ... Dec 14, 2005
Finanzen.net, The acquisition of Abgenix provides Amgen with full ownership ofone of its most important advanced pipeline products, panitumumab.Working closely with Abgenix ...
Biotech behemoth beefs up Dec 15, 2005
Los Angeles Daily News, Amgen executives said in a conference call that Fremont-based Abgenix's colorectal cancer drug panitumumab could eventually contribute $2 billion annually to ...
Amgen to purchase Abgenix Dec 15, 2005
Contra Costa Times, ...a promising cancer drug. The two companies have been working to develop the drug known as panitumumab. Amgen became motivated to ...
Medarex, Cell Genesys up on Abgenix deal Dec 15, 2005
BusinessWeek Amgen announced its intent to buy Abgenix for $2.2 billion on Wednesday, giving the company full ownership of the cancer antibody drug Panitumumab, a fully ...
Amgen to Buy Biotech Partner Abgenix Dec 14, 2005
Smartmoney.com Amgen said the acquisition of Abgenix, which makes human therapeutic antibodies, will give it full ownership of the anti-cancer treatment Panitumumab. ...
Amgen buying Abgenix for $2.2B Dec 14, 2005
Bizjournals.com, Amgen said the acquisition of Abgenix will give it full ownership of the anti-cancer treatment Panitumumab which the companies have been co-developing. ...
Amgen buys rival to secure cancer drug Dec 15, 2005
Australian, The companies already had close ties because of a co-development agreement for the drug panitumumab, which recently completed final phase three trials and will ...
UPDATE: Amgen To Buy Abgenix For $2.2 Bln Dec 14, 2005
Business Online, Amgen and Abgenix already have collaborated on developing two major drug candidates, the cancer therapy panitumumab and denosumab, a treatment for osteoporosis ...
Amgen acquires Abgenix for $2.2B Dec 14, 2005
United Press International THOUSAND OAKS, Calif., Dec. 14 (UPI) -- Amgen said Wednesday it has bought Abgenix and Abgenix's anti-cancer drug panitumumab for $2.2 billion. ...
Amgen buys Abgenix to secure cancer drug rights Dec 15, 2005
Pharma Times (subscription), The drug, panitumumab, is in late-stage clinical development for colorectal cancer and could plug a near-term gap in Amgen's product pipeline, with peak sales ...
Amgen "buy" Dec 20, 2005
New Ratings The company is expected to release late-stage clinical data for panitumumab in colorectal cancer in 1Q and 2Q, and receive the FDA approval in 2H06, Merrill ...
Amgen to buy Abgenix Dec 15, 2005
MarketWatch Amgen and Abgenix have been collaborating on developing two major drug candidates, most notably the cancer therapy panitumumab. ...
Amgen Offers To Buy Out Abgenix For $2.2B In Cash Dec 14, 2005
BioWorld Online (subscription), That product is panitumumab, a monoclonal antibody for colorectal cancer partnered with Amgen, which began working with Abgenix on the compound after acquiring ...
Amgen seals deal to buy Abgenix for $2.2 billion Dec 15, 2005
9NEWS.com, The purchase gives Amgen full ownership of panitumumab, a drug for colon, head and neck cancers the companies have been developing jointly since 2002 under an ...
Amgen to buy Abgenix Dec 14, 2005
San Jose Mercury News, The deal gives Amgen full rights to a cancer drug called Panitumumab, which the Thousand Oaks-based company has been developing with Abgenix. ...
Amgen Avoids Profit Sharing, Buys Abgenix Dec 14, 2005
Forbes The companies are currently co-developing promising late-stage cancer drug panitumumab; they expect to file for FDA approval later this week. ...
Amgen to acquire biotech working on cancer drugs Dec 15, 2005
Seattle Times, If Abgenix shareholders and regulators approve the deal, Amgen will acquire all rights to panitumumab, a promising colon-cancer drug the two companies are ...
Amgen to acquire Abgenix for $2.2 billion Dec 16, 2005
Pharmaceutical Business Review 16 Dec 2005, 16:49 GMT - The deal provides Amgen with full ownership of panitumumab, a potential blockbuster anticancer compound that the companies have been ...
Amgen scoops up Abgenix Dec 15, 2005
Inside Bay Area, Instead, Amgen is primarily interested in the experimental colon-cancer drug panitumumab. The two companies currently share 50 percent ...
Mouse-engineering firm fetches $2.2B from Amgen Dec 14, 2005
Newark Star Ledger, ...are developing. Amgen said it thinks sales of the still-experimental drug, called panitumumab, could exceed $2 billion a year. "We ...
Amgen Avoids Profit Sharing, Buys Abgenix Dec 14, 2005
Forbes The two companies are currently co-developing promising late-stage cancer drug panitumumab; the buyout allows Amgen to avoid paying 50% of worldwide profits ...
Antibody companies rally on Abgenix deal Dec 15, 2005
MarketWatch Amgen said its primarily motivation behind the deal was to gain control over a therapeutic antibody called panitumumab, a cancer treatment that Amgen had been ...
Amgen deal sparks interest in small biotech Dec 15, 2005
Reuters Industry analysts gave near unanimous thumbs up to the deal that will give Amgen complete control over the promising cancer drug, panitumumab, that it was co ...
Amgen to buy Abgenix for $2.2 billion in cash Dec 14, 2005
Denver Business Journal, ...to a release on Wednesday, the acquisition of Abgenix provides Amgen with full ownership of one of its most important advanced pipeline products, panitumumab. ...
Amgen to acquire Abgenix for $2.2bn Dec 15, 2005
New Ratings The acquisition would give Amgen full rights to the colon cancer drug, panitumumab, which was being jointly developed by the two companies. ...
Street Chatter: Amgen, E*TRADE Financial, and Lennar Dec 15, 2005
Schaeffers Research, The acquisition will give AMGN complete control of a new cancer treatment panitumumab, which AMGN believes could have peak sales in excess of $2 billion. ...
Zacks.com Announces That Nadine Wong Highlights: Amgen and Abgenix Dec 5, 2005
Business Wire (press release), In early November, Amgen (NASDAQ:AMGN) and Abgenix (NASDAQ:ABGX) announced that a Phase III study of panitumumab met the primary endpoint of improving ...
World's Largest Biotech Company Makes $2.2 Billion Acquisition Dec 14, 2005
All Headline News ...for about $2.2 billion in cash. If approved by regulators, the cancer drug, panitumumab, would be the first cancer treatment from Amgen. ...
Imclone Systems shares down on report Dec 5, 2005
BusinessWeek In a research note, SG Cowen & Co. analyst Eric Schmidt said that he expects panitumumab, a cancer drug developed by biotech companies Amgen Inc. ...
Amgen to Acquire Abgenix for $2.2 Billion in Cash (Update1) Dec 14, 2005
Bloomberg ...``This investment reflects Amgen's commitment to our pipeline and our growing confidence in the future success of both panitumumab and denosumab.''.
Amgen to acquire Abgenix for $2.2 billion Dec 14, 2005
ABC News ...earnings per share in 2006 and 2007 by 5 cents to 10 cents, and to add to earnings thereafter, assuming commercial success of panitumumab, the experimental ...
Biotech titan Amgen offers $2.2 billion for Abgenix Dec 14, 2005
San Jose Mercury News, ...developing. Amgen said Wednesday that it believes sales of the still-experimental drug called panitumumab could exceed $2 billion a year. ...
Eye On Stocks For Thursday, Dec. 15 Dec 14, 2005
Forbes ...gain in after-hours trading. The companies are currently developing promising cancer drug panitumumab. The transaction will allow ...
Amgen paying $2.2B for Abgenix Dec 14, 2005
Monsters and Critics.com, Buying Abgenix provides Amgen full ownership of panitumumab, 'one of its most important advanced pipeline products,' Amgen said Wednesday in a statement. ...
AstraZeneca reviews Abgenix link after Amgen deal Dec 15, 2005
Scotsman, Amgen has agreed to pay about $2.2 billion (1.24 billion pounds) in cash for Abgenix, giving it full control of a cancer drug called panitumumab that the two ...
Early Stocks in Motion Dec 15, 2005
TheStreet.com ..."Amgen has been intimately involved in all aspects of the development and commercialization of panitumumab over the last few years, providing us with ...
Drug Stocks Boosted By Amgen Buyout Dec 17, 2005
Forbes The companies are currently developing panitumumab, and the deal allows Amgen to avoid paying Abgenix 50% of worldwide profit for the promising cancer treatment ...
Biotech Stocks Amgen, Merck gains help boost sector Dec 15, 2005
MarketWatch See full story. Amgen said the deal would allow it to fully control commercialization of the companies' jointly developed cancer drug candidate, panitumumab. ...
Immunomedics shares rise on pending deal Dec 15, 2005
BusinessWeek Piros added in a report that Amgen Inc.'s decision to buy Abgenix Inc., which is developing a targeted cancer therapy called panitumumab, "indicates that ...
Digest: Wal-mart buying stores in Brazil; Amgen acquires partner Dec 14, 2005
Austin American-Statesman (subscription), Amgen and Abgenix are partners on an experimental colon-cancer drug called panitumumab, which was found to work better than expected during a large human trial ...
Morning Briefing Dec 15, 2005
Hartford Courant, Amgen said Wednesday that it believes sales of the still experimental drug called panitumumab could exceed $2 billion a year. MOUNTAIN VIEW, Calif. ...
Opening View: Consumer Prices Fall at Fastest Rate Since 1949 Dec 15, 2005
Schaeffers Research, AMGN highlighted the prospects for cancer treatment Panitumumab, which, it said, could have sales in excess of $2 billion, although the drug has yet to be ...
Amgen "outperform," target price raised Dec 15, 2005
New Ratings The acquisition offers the company 100% control of the cancer drug, panitumumab, the BLA for which is expected to be filed later this week, the analysts say. ...
Amgen Acquires Abgenix Dec 15, 2005
socalTech.com, Amgen said that it has previously been working with Abgenix on its pipeline product panitumumab, which is targeted at treatment of metastatic colorectal cancer ...
Options Update: Options Players Cry "Give Me Liberty Media!" Dec 15, 2005
Schaeffers Research, ...$2.2 billion. AMGN made the move in order to gain complete control over Panitumumab, the AMGN/ABGX developed cancer treatment. AMGN ...
ImClone Shares Could See 25% Downside Dec 7, 2005
Forbes Schmidt expects Amgen/Abgenix's cancer drug panitumumab to compete well with Erbitux and eventually capture a majority of the anti-EGFR antibody market ...
Pharma Reformulates Dec 5, 2005
Chemical & Engineering News There has also been positive data for Abgenix and Amgen's panitumumab, a monoclonal antibody for metastatic colorectal cancer that is due to be submitted for ...
|
|
